{"id":14427,"date":"2014-02-05T07:07:01","date_gmt":"2014-02-05T12:07:01","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=14427"},"modified":"2014-02-05T06:54:14","modified_gmt":"2014-02-05T11:54:14","slug":"pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427","title":{"rendered":"Pfizer  Inc. (NYSE:PFE) Facing Immense Pressure From Nektar Therapeutics"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 02\/05\/2014 (wallstreetpr) &#8211; <b>Pfizer Inc. (NYSE:PFE) <\/b>recently announced the successive trial of its new drug that claims to be effective and reliable in the treatment of mild pain<a href=\"http:\/\/www.dailyfinance.com\/2014\/02\/04\/can-nektar-therapeutics-beat-pfizer-inc\/\">. Nektar Therapeutics<\/a> on the other hand is sneaking from behind with immense pressure with its innovative approach that is sure to give Pfizer a run for its money. Pfizer setbacks begun with the rejection of its new drug remoxy. This was later resolved with the company meeting primary efficacy endpoint in its late trial stages. The drug making company is also inline to introduce a new drug into the market which has passed tests that will be used to address issues of breast cancer in women.<\/p>\n<p style=\"text-align: justify;\"><b>Pfizer Ex Dividend<\/b><\/p>\n<p style=\"text-align: justify;\">Pfizer Inc. (NYSE:PFE) has announced that its plans to begin the trading of its ex dividend as of February 5, 2014 with a cash dividend <a href=\"http:\/\/www.nasdaq.com\/article\/pfizer-inc-pfe-exdividend-date-scheduled-for-february-05-2014-cm323324\">of $0.26 expected<\/a> to be paid on March 4, 2014. Shareholders who will have purchased the company\u2019s stock prior to the date of the ex-dividend will be eligible for cash dividend payment. The offer is expected to represent an increase of up to 8.33% compared to the prior\u2019s quarter.<\/p>\n<p style=\"text-align: justify;\"><b>\u00a0Pfizer current market status<\/b><\/p>\n<p style=\"text-align: justify;\">Pfizer Inc. (NYSE:PFE) which commands a market cap of $205.97 billion closed trading on Tuesday evening at a high of $31.44 a massive increase of 2.75%. The company\u2019s shares are currently priced at 13.48X the full year forecasted earnings, this essentially means they are a bit expensive compared to the industries 9.7X earnings. Pfizer consensus earnings are at a high of $0.55 per share compared to that of year ago, its stock has a dividend yield of 3.5% wit. The shares are currently rated as a buy in 7 analysts firms with only 1 analyst rating it as a sell and 4 as a hold. The average traded shares per day for the company stands at 24.3 million.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 02\/05\/2014 (wallstreetpr) &#8211; Pfizer Inc. (NYSE:PFE) recently announced the successive trial of its new drug that claims to be effective and reliable in [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":5121,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[993,2745],"stock_ticker":[],"class_list":["post-14427","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nysepfe","tag-pfizer-inc-nysepfe","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pfizer Inc. (NYSE:PFE) Facing Immense Pressure From Nektar Therapeutics - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Inc. (NYSE:PFE) Facing Immense Pressure From Nektar Therapeutics - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 02\/05\/2014 (wallstreetpr) &#8211; Pfizer Inc. (NYSE:PFE) recently announced the successive trial of its new drug that claims to be effective and reliable in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-02-05T12:07:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Pfizer Inc. (NYSE:PFE) Facing Immense Pressure From Nektar Therapeutics\",\"datePublished\":\"2014-02-05T12:07:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427\"},\"wordCount\":315,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg\",\"keywords\":[\"NYSE:PFE\",\"Pfizer Inc (NYSE:PFE)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427\",\"name\":\"Pfizer Inc. (NYSE:PFE) Facing Immense Pressure From Nektar Therapeutics - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg\",\"datePublished\":\"2014-02-05T12:07:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg\",\"width\":400,\"height\":300},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Inc. (NYSE:PFE) Facing Immense Pressure From Nektar Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pfizer Inc. (NYSE:PFE) Facing Immense Pressure From Nektar Therapeutics - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427","og_locale":"en_US","og_type":"article","og_title":"Pfizer Inc. (NYSE:PFE) Facing Immense Pressure From Nektar Therapeutics - Wall Street PR","og_description":"Boston, MA 02\/05\/2014 (wallstreetpr) &#8211; Pfizer Inc. (NYSE:PFE) recently announced the successive trial of its new drug that claims to be effective and reliable in [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-02-05T12:07:01+00:00","og_image":[{"width":400,"height":300,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Pfizer Inc. (NYSE:PFE) Facing Immense Pressure From Nektar Therapeutics","datePublished":"2014-02-05T12:07:01+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427"},"wordCount":315,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg","keywords":["NYSE:PFE","Pfizer Inc (NYSE:PFE)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427","url":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427","name":"Pfizer Inc. (NYSE:PFE) Facing Immense Pressure From Nektar Therapeutics - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg","datePublished":"2014-02-05T12:07:01+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg","width":400,"height":300},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-facing-immense-pressure-from-nektar-therapeutics-14427#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Pfizer Inc. (NYSE:PFE) Facing Immense Pressure From Nektar Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/14427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=14427"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/14427\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/5121"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=14427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=14427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=14427"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=14427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}